Lonza Group AG (LONN)

Currency in EUR
205.00
0.00(0.00%)
Closed·
Showing Lonza Group historical data. For real-time data please try another search
Day's Range
204.00205.00
52 wk Range
0.00205.00
Key Statistics
Bid/Ask
21.16 / 230.00
Prev. Close
204.9
Open
204.4
Day's Range
204-205
52 wk Range
0-0
Volume
-
Average Volume (3m)
184
1-Year Change
0%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Lonza Group AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Lonza Group AG Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, development, and manufacturing, such as particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. Its Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Industry
-
Sector
-
Employees
19299
Market
Germany

Lonza Group AG Earnings Call Summary for Q1/2025

  • Lonza projects ~20% sales growth in CDMO business for 2025, with core EBITDA margin near 30%
  • New API facility in Wyss and large-scale drug product facility in Stein, Switzerland under development
  • Expanding manufacturing in Asia with capsule production facilities in India and China
  • Preparing for potential CHI business carve-out in 2025, transitioning to new business platforms
  • Executives confident in 2025 outlook despite FX headwinds and potential geopolitical challenges
Last Updated: 09/05/2025, 14:46
Read Full Transcript

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.39%
Dividend Yield
0.73%
Industry Median -
Annualised payout
4.27
Paid annually
5-Years Growth
+7.78%
Growth Streak

Earnings

Latest Release
Jul 23, 2025
EPS / Forecast
6.07 / --
Revenue / Forecast
3.58B / --
EPS Revisions
Last 90 days

LONN Income Statement

People Also Watch

97.52
NOVN
+1.34%
581.80
ZURN
+1.43%
53.86
ABBN
-0.48%
70.06
ALCC
+1.24%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.